Job description
As an Upstream Bioprocess Development Scientist at Elanco, you will be part of the Bioprocess Development team focused on delivering robust upstream platforms for the Biotherapeutic portfolio. This role involves advancing upstream process development from flask models to bioreactor scales while collaborating with downstream, formulations, and analytical scientists. You will contribute to a culture of innovation and scientific excellence, ensuring high-quality processes for large molecules. Your work will directly impact the development of products that improve animal health.
Requirements
- Bachelor’s Degree in Biology, Molecular Biology, Microbiology, or related scientific discipline.
- Minimum of five years of hands-on experience working with mammalian cell lines or similar.
- Strong laboratory skills in cell culture and bioreactor operation.
- Foundational knowledge of bioprocess and Design of Experiments principles.
Responsibilities
- Conceive, plan, schedule, and execute laboratory experiments across multiple models and scales.
- Apply Quality by Design principles and Design of Experiments methodologies to optimize product quality and yield.
- Maintain laboratory infrastructure and ensure adherence to safety protocols.
- Analyze and interpret complex datasets to inform experimental design.
- Author technical reports, SOPs, and sections for regulatory submissions.
- Lead process troubleshooting and provide technical coverage at manufacturing facilities.
Benefits
- Employees at Elanco are often offered competitive compensation with annual bonus and equity eligibility, retirement plans (including a U.S. 401(k)), and comprehensive health coverage—medical, dental, vision, company-paid life and disability—and even pet insurance. Time-off and flexibility typically include generous PTO, U.S. mid-year and year-end paid shutdown weeks, parental leave, and flexible/remote work options. Employees also benefit from strong development programs (onboarding, course libraries, mentorship, nine ERGs, and tiered leadership programs) that support both professional growth and community involvement.
H-1B filing history
Public USCIS petition and DOL LCA counts · latest USCIS FY2026, LCA FY2026
Combined across 2 filing entities: Elanco Us Inc, Elanco Animal Health Inc
As of Aug 23, 2026
Initial approvals
4
FY2026
Approval rate
100.0%
FY2026
LCA certified
12
FY2026
Entry-level share
0.0%
FY2026
Initial approvals YoY
+3%
Trend
LCA certified YoY
-25%
Trend
Initial approvals by fiscal year
Approval rate by fiscal year
Continuing vs initial approvals
LCA certified positions by quarter
LCA certified positions by fiscal year
Based on public USCIS and DOL filings; not a sponsorship guarantee.
Is this posting expired or inaccurate?
